Cladribine
- Generic Name
- Cladribine
- Brand Names
- Litak, Mavenclad
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12ClN5O3
- CAS Number
- 4291-63-8
- Unique Ingredient Identifier
- 47M74X9YT5
- Background
An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia.
- Indication
For the treatment of active hairy cell leukemia (leukemic reticuloendotheliosis) as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. Also used as an alternative agent for the treatment of chronic lymphocytic leukemia (CLL), low-grade non-Hodgkin's lymphoma, and cutaneous T-cell lymphoma.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Cutaneous T-Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Non-Hodgkin's Lymphomas, Active confirmed by clinical features, confirmed by imaging features relapsing multiple sclerosis (MS)
Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia
Phase 3
Completed
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Swiss Group for Clinical Cancer Research
- Target Recruit Count
- 100
- Registration Number
- NCT00003746
- Locations
- 🇨🇭
Inselspital Bern, Bern, Switzerland
Phase II Pilot Study of Cladribine (2-Chlorodeoxyadenosine; 2-CdA) for Early Stage Primary Sclerosing Cholangitis
Phase 2
Completed
- Conditions
- Cholangitis, Sclerosing
- First Posted Date
- 2000-02-25
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 5
- Registration Number
- NCT00004762
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath